Clinical trials: CYP2C19 Polymorphism
Healthy
Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide
The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.
- Trial name
- NCT00806013
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of…
- Trial name
- NCT06283888
- Testing
- CYP2C19 Genotype Guided DAPT, Conventional DAPT
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Zunyi Medical College
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
Systemic Lupus Erythematosus
Cyclophosphamide in Lupus Nephritis
Cyclophosphamide is widely used in the treatment of cancer and autoimmune diseases such as lupus nephritis. However, there is considerable variability in the response to cyclophosphamide treatment.
- Trial name
- NCT00441220
- Where
- 3 sites in New Zealand
- Volunteers
- 60 people
- Sponsor
- University of Auckland, New Zealand
Platelet Aggregation Inhibitors
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients
Background: Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel.
- Trial name
- NCT02711410
- Testing
- Clopidogrel
- Volunteers
- 518 people
- Sponsor
- National Cerebral and Cardiovascular Center, Japan
Genotype, Pharmacokinetic
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
Diabetes mellitus is a growing global disease now and future, and in China, 1.2 million peoples per year have been diagnosed as diabetes mellitus. 90% diabetes mellitus patient is Type 2 diabetes mellitus.
- Trial name
- NCT01082796
- Testing
- Glipizide
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Biological Collection for the Purpose of Exploring Genetic and Clinical-biological Factors Associated With Variability in Response to Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy
The European Medicines Agency has required pre-treatment genotyping of CYP2C19 to determine the initial and maximum dosage, in order to avoid overexposure to mavacamten associated with a decrease in ventricular ejection fraction…
- Trial name
- MAVA PG (NCT07439952)
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy
Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism
To study the impact of CYP2C19 polymorphism on escitalopram pharmacokinetics and pharmacodynamics measured as changes in pupil diameter
- Trial name
- NCT00397059
- Testing
- Escitalopram
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Stomach Ulcer
Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole
A clinical trial to investigate the influence of CYP2C19 polymorphism on pharmacokinetic/pharmacodynamic characteristics of omeprazole in healthy Korean volunteers
- Trial name
- NCT02299687
- Testing
- Omeprazole
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
Genotype Information and Functional Testing Study
This study is a sub-study of GRAVITAS (clinicaltrials.gov identifier NCT00645918). The purpose of this study is to assess which genes influence residual platelet reactivity on standard dose clopidogrel therapy, and also to…
- Trial name
- GIFT (NCT00992420)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Scripps Health
Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
This randomized controlled trial will evaluate whether the use of pharmacogenetic testing through a Medication Therapy Management (MTM) program has a beneficial impact on drug therapy problems.
- Conditions
- Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Trial name
- NCT02428660
- Testing
- Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- Genelex Corporation
Breast Cancer Patients
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients
Genetic polymorphisms of metabolic enzymes may influence the metabolism of Doxorubicin-Cyclophosphamide regimen in breast cancer patients. the investigators want to 1.
- Trial name
- NCT04581967
- Testing
- polymorphism analysis, Doxorubicin-Cyclophosphamide regimen
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Damanhour University
Healthy
Bioavailability and Metabolism of Voriconazole in Relation to Its Modulation by the CYP2C19 Genetic Polymorphism
The purposes of this study are: To determine the absolute bioavailability of voriconazole after a single oral dose (400 mg voriconazole [VFEND brand]) in comparison to intravenous (i.v.) administration (400 mg VFEND, equivalent…
- Trial name
- NCT00175994
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD)
Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events
Several studies have shown that the efficacy of clopidogrel for secondary prevention of major adverse cardiovascular events (MACE), including acute coronary syndrome, depends on the polymorphism of the CYP2C19 gene.
- Conditions
- Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified
- Trial name
- UF-GENOTYPE (NCT06855394)
- Where
- 2 sites in United States
- Volunteers
- 13,000 people
- Sponsor
- University of Florida
Coronary Artery Disease
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Numerous studies have shown that pharmacodynamics (PD) response profiles vary among clopidogrel treated patients and that individuals with reduced response have an increased risk of recurrent ischemic events.
- Trial name
- NCT02065479
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Florida
Healthy
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects
To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy subjects carriers of a mutated allele (*2) associated with CYP2C19 deficiency and non responders to the usual regimen of 75 mg once daily
- Trial name
- NCT00413608
- Testing
- Clopidogrel
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Neoplasms, Survival Analysis
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6…
- Conditions
- Breast Neoplasms, Survival Analysis, Antineoplastic Agents, Therapeutic Uses
- Trial name
- NCT01169792
- Testing
- tamoxifen
- Where
- 2 sites in South Korea
- Sponsor
- Yonsei University
CYP2C19 Polymorphism, H.Pylori Infection
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
Background: Triple therapy efficacy against Helicobacter pylori is low worldwide, thus alternatives must be sought to improve eradication. Aim: To determine CYP2C19 genetic polymorphism effect on H. pylori eradication.
- Conditions
- CYP2C19 Polymorphism, H.Pylori Infection, Therapy
- Trial name
- NCT03650543
- Testing
- amoxicillin clarithromycin omeprazole 1, amoxicillin clarithromycin omeprazole 2
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Javeriana University
Interaction
The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers
The aim of this study is to investigate the effects of genetic polymorphisms on pharmacokinetic and pharmacodynamic interactions of clopidogrel and cilostazol in Korean healthy adult volunteers.
- Trial name
- NCT01482117
- Testing
- Clopidogrel, Cilostazol, Clopidogrel/Cilostazol
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Inje University
Myocardial Infarction
Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)
In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogrel and ticagrelor 180 mg loading dose will…
- Trial name
- NCT03613857
- Testing
- Clopidogrel, Ticagrelor 90mg
- Where
- Egypt
- Volunteers
- 1,022 people
- Sponsor
- Cairo University